Burning Rock Biotech (BNR) Revenue (2019 - 2026)

Burning Rock Biotech (BNR) has reported Revenue for 8 consecutive years, with $15.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue fell 14.67% year-over-year to $15.6 million; the TTM figure through Mar 2026 stood at $72.9 million (changed 0.48% YoY), while the FY2025 annual figure was $77.2 million, up 9.18% from the prior year.
• Revenue came in at $15.6 million for Q1 2026 at Burning Rock Biotech, down from $18.1 million in the prior quarter.
• The five-year high for Revenue was $21.7 million in Q3 2022, with the low at $15.6 million in Q1 2026.
• Average Revenue over 5 years is $18.9 million, with a median of $18.5 million recorded in 2025.
• Across the five-year window, Revenue soared 31.37% in 2022 and fell 19.56% in 2023, its largest moves.
• Year by year, Revenue stood at $20.6 million in 2022, then dropped by 17.3% to $17.1 million in 2023, then grew by 1.24% to $17.3 million in 2024, then grew by 4.62% to $18.1 million in 2025, then fell by 13.36% to $15.6 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $15.6 million, $18.1 million, and $18.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.